| Original language | English |
|---|---|
| Journal | Journal of the European Academy of Dermatology and Venereology |
| Volume | 36 |
| Issue number | 7 |
| Pages (from-to) | e580-e583 |
| ISSN | 0926-9959 |
| DOIs | |
| Publication status | Published - Jul 2022 |
Keywords
- Hidradenitis Suppurativa/genetics
- Humans
- Mycobiome
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Amplicon sequencing demonstrates comparable follicular mycobiomes in patients with hidradenitis suppurativa compared with healthy controls. / Ring, H. C.; Thorsen, J.; Fuursted, K. et al.
In: Journal of the European Academy of Dermatology and Venereology, Vol. 36, No. 7, 07.2022, p. e580-e583.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Amplicon sequencing demonstrates comparable follicular mycobiomes in patients with hidradenitis suppurativa compared with healthy controls
AU - Ring, H. C.
AU - Thorsen, J.
AU - Fuursted, K.
AU - Bjarnsholt, T.
AU - Bay, L.
AU - Egeberg, A.
AU - Ingham, A. C.
AU - Vedel Nielsen, H.
AU - Frew, J. W.
AU - Saunte, D. M.L.
AU - Thomsen, S. F.
AU - Jemec, G. B.
N1 - Funding Information: Dr. Ring has received research funding from the Kgl Hofbundtmager Aage Bang Foundation and honoraria as speaker from Leo Pharma. Dr. Thorsen. None. Ms. Bay None. Prof. TB none. Dr. KF None. Ms. AI None. Dr. Frew has conducted advisory work for Janssen, Boehringer‐Ingelheim, Pfizer, Kyowa Kirin, LEO Pharma, Regeneron, Chemocentryx, Abbvie and UCB, participated in trials for Pfizer, UCB, Boehringer‐Ingelheim, Eli Lilly, CSL, Janssen and received research support from Ortho Dermatologics and Sun Pharma. Mr. HV None. Dr. Thomsen has been a speaker and/or served on advisory boards for AbbVie, Almirall, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi and UCB, and has received research support from AbbVie, Janssen, LEO Pharma, Novartis, Sanofi and UCB. Dr. Egeberg has received research funding from Pfizer, Eli Lilly, Novartis, Bristol‐Myers Squibb, AbbVie, Janssen Pharmaceuticals, the Danish National Psoriasis Foundation, the Simon Spies Foundation, and the Kgl Hofbundtmager Aage Bang Foundation, and honoraria as consultant and/or speaker from AbbVie, Almirall, Leo Pharma, Zuellig Pharma Ltd., Galápagos NV, Sun Pharmaceuticals, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly and Company, Novartis, Galderma, Dermavant, UCB, Mylan, Bristol‐Myers Squibb, and Janssen Pharmaceuticals. Dr. DMS has received honoraria from Novozymes and Leo Pharma. Dr. GJ has received research grants from Abbvie, Leo Foundation, Afyx, InflaRx, Janssen, Novartis, UCB, Regeneron, Sanofi, Union Therapeutics and consulting fees from Coloplast, Chemocentryx, Leopharma, Incyte, Kymera and VielaBio.
PY - 2022/7
Y1 - 2022/7
KW - Hidradenitis Suppurativa/genetics
KW - Humans
KW - Mycobiome
UR - http://www.scopus.com/inward/record.url?scp=85126823509&partnerID=8YFLogxK
U2 - 10.1111/jdv.18075
DO - 10.1111/jdv.18075
M3 - Letter
C2 - 35285081
AN - SCOPUS:85126823509
VL - 36
SP - e580-e583
JO - Journal of the European Academy of Dermatology and Venereology
JF - Journal of the European Academy of Dermatology and Venereology
SN - 0926-9959
IS - 7
ER -